At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 59 enrolled
Drug / intervention
Nesiritide +1 moredrug
Likely dose
Nesiritide 0.006 mcg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Nesiritide Therapy for the Preservation of Left Ventricular Function Post Anterior Myocardial Infarction
In Brief
A Phase 2 clinical trial evaluating Nesiritide and Placebo for Acute Myocardial Infarction. Completed, enrolled 59 participants across 2 sites.
Detailed Summary
The purpose of this study is to determine the efficacy of intravenous human beta natriuretic peptide (BNP, Nesiritide) as compared to placebo to prevent adverse post acute myocardial infarction left ventricular remodeling.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myocardial Infarction
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2006
First PostedDec 2007
Primary CompletionNov 2012
Study CompletionApr 2013
TodayJul 2026
First PostedDec 14, 2007
Enrollment StartSep 1, 2006
Primary CompletionNov 1, 2012
Study CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 18.6 years ago
Interventions
Nesiritidedrug
Infusion of 72 hours of IV nesiritide at 0.006 mcg/kg/min.
Placebodrug
Infusion of 72 hours of saline solution (packaged to match active comparator)